Valneva outlines €170M-€180M sales target for 2025 with focus on IXCHIQ and Lyme vaccine developments
Valneva anticipates total product sales of €170 million to €180 million and total revenues of €180 million to €190 million for 2025, driven by increased IXCHIQ sales and growth in IXIARO and DUKORAL.
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million ...
The Manila Times1d
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments ...
USA Today2d
New York City officials report second measles case as Texas outbreak continues
As the measles outbreak continues to spread in Texas, cases have been reported in New Jersey as well as a second case in New York City. The New York City Department of Health said that one ...
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Frontiers6d
Commentary: Inactivated rabies virus vectored MERS-Coronavirus vaccine induces protective immunity in mice, camels, and alpacas
Compared with the live-attenuated vaccine, the IRVV shows a good safety profile in vivo, as evidenced by neither virus mutation nor virulence reversion occurring in IRVV-vaccinated animals. A chimeric ...